Anti-Angiogenesis in Glioblastoma: The Clinical Consequences of Redundancy and Evasion?

ISSN: 2211-5536 (Online)
ISSN: 2211-5528 (Print)

Volume 4, 2 Issues, 2015

Download PDF Flyer

Current Angiogenesis

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Guo-Chang Fan, PHD
Dept. of Pharmacology and Cell Biophysics
University of Cincinnati College of Medicine

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Anti-Angiogenesis in Glioblastoma: The Clinical Consequences of Redundancy and Evasion?

Current Angiogenesis, 2(2): 126-134.

Author(s): Richard Mair and Colin Watts.

Affiliation: Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.


Glioblastoma Multiforme (GBM) is recognised as one of the most hypervascular human tumors. Various drugs have been developed that target pro-angiogenic factors in an attempt to disrupt the blood supply and thus arrest tumor growth. Clinical studies have largely been in groups of unselected patients and have encompassed both primary and recurrent GBM. Despite initial promise, in both pre-clinical models and preliminary clinical trials, sustained therapeutic benefit in the clinic has yet to be demonstrated. In this review article we present the most up to date clinical trials and aim to elucidate the common mechanisms by which GBM may be escaping these therapies. We also discuss other potential mechanisms of action and possible future indications for anti-angiogenic medication.


Anti-angiogenesis, antibodies, clinical trials, glioblastoma, small molecule inhibitors, VEGF.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 2
Issue Number: 2
First Page: 126
Last Page: 134
Page Count: 9
DOI: 10.2174/2211552802666140128000111

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science